Related Experiment Videos
Superficial bladder cancer: the role of interferon-alpha
A S Belldegrun1, J R Franklin, M A O'Donnell
1Division of Urologic Oncology, UCLA School of Medicine, Los Angeles, California, USA.
The Journal of Urology
|May 23, 1998
Summary
Recombinant interferon-alpha shows promise for superficial bladder cancer, especially after BCG or chemotherapy failure. Further studies will clarify its role alongside BCG and chemotherapy for optimal treatment strategies.
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Superficial transitional cell carcinoma (TCC) treatment often involves intravesical agents.
- Bacillus Calmette-Guerin (BCG) is highly effective but has toxicities and relapse rates.
- Alternative and adjunct therapies are needed for TCC management.
Purpose of the Study:
- To evaluate clinical experience with recombinant interferon-alpha for superficial TCC.
- To determine the optimal use of recombinant interferon-alpha within current treatment paradigms.
- To assess interferon-alpha's efficacy in BCG-refractory or BCG-failed TCC cases.
Main Methods:
- Review and discussion of available data at a consensus conference.
- Consensus-based conclusions and recommendations from study authors.
- Focus on clinical experience and treatment outcomes.
Main Results:
- Recombinant interferon-alpha demonstrates efficacy in primary and recurrent superficial TCC.
- Interferon-alpha exhibits minimal toxicity compared to BCG.
- Responses observed in patients refractory to BCG or chemotherapy.
Conclusions:
- Recombinant interferon-alpha is valuable as second-line therapy for superficial TCC after BCG or chemotherapy failure.
- Potential synergistic effects of interferon-alpha with BCG or chemotherapy warrant investigation.
- Proposed randomized study to compare interferon-alpha, BCG, and combination therapies for optimal integration.